GoodRx for Healthcare Professionals7 Things to Know About Retatrutide for Weight Loss: Dosages, Clinical Trial Results, and More

Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, produced 24% average body weight loss in phase 2 trials and nearly 29% loss over 68 weeks in obese patients with knee osteoarthritis, outperforming every currently approved weight-loss medication. Phase 3 trials are expected to conclude in early 2026, with potential FDA approval in 2027 if Eli Lilly submits promptly.

Clinical Considerations

• Triple-hormone mechanism is clinically distinct: glucagon receptor agonism accelerates metabolism and fat breakdown, adding to GIP/GLP-1 appetite suppression in a way that current dual or single agonists cannot replicate
• 29% weight loss with concurrent osteoarthritis pain relief in phase 3 knee OA data signals broad musculoskeletal and metabolic application beyond pure weight management
• GI side effect profile mirrors existing GLP-1 agents: nausea, vomiting, diarrhea, and constipation rated mild to moderate, most prominent during dose escalation
• Counterfeit retatrutide is already circulating; the FDA has issued warnings against unapproved sources including compounding pharmacies selling the not-yet-approved agent

Practice Applications

• Counsel patients asking about retatrutide that it remains unapproved; purchasing from compounding pharmacies or online sources is illegal and carries contamination and dosing risks
• Monitor phase 3 completion announcements in early 2026 and Eli Lilly’s FDA submission timeline to prepare patients currently on semaglutide or tirzepatide for future transition conversations
• Identify patients with obesity plus knee osteoarthritis as a priority population if retatrutide receives approval, given the dual analgesic and weight-loss phase 3 signal
• Document current GLP-1 therapy and weight-loss trajectory now to establish baselines for future comparative discussions as the drug class expands

More in Obesity/Weight Management